Is Radiotherapy Necessary for Stage 1 Testicular Seminoma?.
10.3857/jkstro.2009.27.2.49
- Author:
Jung Ae LEE
1
;
Won PARK
;
Do Hoon LIM
;
Yong Chan AHN
;
Seung Jae HUH
;
Jeong Il YU
;
Han Yong CHOI
;
Hyun Moo LEE
;
Eun Yoon CHO
Author Information
1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wonro.park@samsung.com
- Publication Type:Original Article
- Keywords:
Seminoma;
Radical orchiectomy;
Radiation therapy;
Surveillance
- MeSH:
Compliance;
Cryptorchidism;
Follow-Up Studies;
Germ Cells;
Humans;
Lymph Nodes;
Male;
Orchiectomy;
Recurrence;
Retrospective Studies;
Seminoma
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2009;27(2):49-54
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To report on the clinical outcome of patients with stage I testicular seminoma by postoperative radiotherapy (PORT) or surveillance after radical inguinal orchiectomy. MATERIALS AND METHODS: This study is a retrospective review of 32 stage I pure seminoma patients treated between 1996 and 2005 at the Samsung Medical Center. Twenty two of the patients were treated by PORT, which was directed at the paraaortic lymphatics with a median dose of 25.2 Gy in 14 fractions for 3 weeks. The 10 remaining patients were managed by surveillance. The median follow-up period was 96 months with a range of 24 to 155 months. RESULTS: Clinically, most patients presented with a testicular mass or discomfort. Two of the patients had a history of undescended testes. Pathologically, 23 of the patients had intratubular germ cell neoplasia with seminoma. Both recurrence-free survival (RFS) and overall survival (OS) rates of patients treated by PORT were 100%. In the control group, 1 of the 10 patients suffered a para-aortic lymph node relapse. The RFS and OS rates of the surveillance group were 88.9% and 100%, respectively. CONCLUSION: No difference in survival was observed between the two groups. Moreover, symptom recurrence was only observed in 1 patient in the control group. The use of PORT may reduce the risk of relapse. With the availability of effective diagnostic and salvage modalities, surveillance monitoring may be considered for patients in good compliance.
